China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)

Yuankai Shi¹, Yan Sun¹, Cuimin Ding¹+28

• ¹1 Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China ; 2 Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China ; 3 Tianjin Medical University Cancer Institute & Hospital, Tianjin 300070, China ; 4 Shenzhen People's Hospital, Shenzhen 518020, China ; 5 The Second Military Medical University Changhai Hospital, Shanghai 200433, China ; 6 Fudan University Zhongshan Hospital, Shanghai 200032, China ; 7 Jiangsu Cancer Hospital, Nanjing 210009, China ; 8 The 307th Hospital of Chinese People's Liberation Army, Beijing 100071, China ; 9 Chinese People's Liberation Army General Hospital, Beijing 100853, China ; 10 Beijing Cancer Hospital, Beijing 100142, China ; 11 Jiangsu Province Hospital, Nanjing 210029, China ; 12 Qinghai University Affiliated Hospital, Xining 810000, China ; 13 The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510000, China ; 14 Zhejiang Cancer Hospital, Hangzhou 310022, China ; 15 Beijing Chest Hospital, Capital Medical University, Beijing 101149, China ; 16 Harbin Medical University Cancer Hospital, Harbin 150081, China ; 17 The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China ; 18 Nanfang Medical University Nanfang Hospital, Guangzhou 510515, China ; 19 Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai 200433, China ; 20 The First Affiliated Hospital, Zhejiang University, Hangzhou 310003, China ; 21 Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China ; 22 Changzhou Fourth People's Hospital, Changzhou 213001, China ; 23 Fujian Cancer Hospital, Fuzhou 350014, China.